Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$301.94 USD

301.94
2,316,263

+5.06 (1.70%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $302.01 +0.07 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod

by Zacks Equity Research

Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.

    Zacks Equity Research

    Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study

    by Zacks Equity Research

    Allergan's (AGN) anti-CGRP candidate, atogepant, successful in mid-stage study, following positive data readouts from two phase III studies on another anti-CGRP candidate, ubrogepant.

      Zacks Equity Research

      Amgen Gets FDA Nod to Add ASPIRE Data on Kyprolis Label

      by Zacks Equity Research

      Amgen (AMGN) gets FDA approval to add overall survival data from the phase III ASPIRE study on the label of its multiple myeloma drug, Kyprolis.

        Zacks Equity Research

        Amgen's (AMGN) Prolia Gets Label Expansion Approval in Europe

        by Zacks Equity Research

        Amgen (AMGN) announces approval for its regulatory application seeking label expansion for Prolia in Europe.

          Zacks Equity Research

          Roche Rituxan Label Expanded by FDA for Pemphigus Vulgaris

          by Zacks Equity Research

          Roche (RHHBY) obtains FDA approval for the label expansion of Rituxan for the treatment of adults with pemphigus vulgaris.

            Zacks Equity Research

            Mylan (MYL) Gets FDA Approval for Biosimilar of Neulasta

            by Zacks Equity Research

            Mylan (MYL) and partner Biocon get a significant boost with the FDA approval for Fulphila, a biosimilar of Amgen's Neulasta.

              Zacks Equity Research

              Merck Presents Positive Melanoma Data on Keytruda at ASCO

              by Zacks Equity Research

              Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.

                Zacks Equity Research

                Novartis Announces Positive Data on Kisqali and Tasigna

                by Zacks Equity Research

                Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.

                  Zacks Equity Research

                  Eli Lilly's Olumiant Gets FDA Nod for Rheumatoid Arthritis

                  by Zacks Equity Research

                  Eli Lilly (LLY) and its partner Incyte announce approval of their arthritis drug, Olumiant, in the United States. The drug will be available at two-fifth of the price of leading RA drugs.

                    Zacks Equity Research

                    Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO

                    by Zacks Equity Research

                    Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.

                      Zacks Equity Research

                      FDA Confirms September Action Date for Teva's Migraine Drug

                      by Zacks Equity Research

                      Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.

                        Zacks Equity Research

                        Novartis Gets Approval for Remicade Biosimilar in Europe

                        by Zacks Equity Research

                        Novartis' (NVS) Sandoz wins approval for a biosimilar version of Remicade in Europe, which should further strengthen its biosimilars portfolio.

                          Zacks Equity Research

                          Why Is Amgen (AMGN) Up 3.7% Since Its Last Earnings Report?

                          by Zacks Equity Research

                          Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            Zacks Equity Research

                            Merck's Keytruda Shows Survival Benefit in Squamous NSCLC

                            by Zacks Equity Research

                            Merck's (MRK) Keytruda in combination with chemotherapy demonstrates better OS and PFS in first-line metastatic squamous NSCLC compared to chemotherapy alone.

                              Zacks Equity Research

                              Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx

                              by Zacks Equity Research

                              Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.

                                Zacks Equity Research

                                Allergan Stock Down Since Q1 Earnings Report: Here's Why

                                by Zacks Equity Research

                                Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.

                                  Zacks Equity Research

                                  Amgen's Label Expansion Application for Prolia Gets FDA Nod

                                  by Zacks Equity Research

                                  Amgen (AMGN) announces FDA approval for its regulatory application seeking label expansion for Prolia.

                                    Zacks Equity Research

                                    Roche (RHHBY) Announces Positive Data on Hemophilia Drug

                                    by Zacks Equity Research

                                    Roche (RHHBY) announces positive data from two phase III studies on hemophilia drug Hemlibra which has further strengthened its hemophilia portfolio.

                                      Zacks Equity Research

                                      Company News For May 21, 2018

                                      by Zacks Equity Research

                                      Companies in the news are: PYPL,AMGN,TTD,CBS

                                        Zacks Equity Research

                                        Migraine Space in Focus as AMGN/NVS' Aimovig Gets FDA Nod

                                        by Zacks Equity Research

                                        Migraine is one of the top 10 causes of years lived with disability globally. With Aimovig receiving FDA approval for treatment of migraine, investors' attention is on future regulatory decisions.

                                          Zacks Equity Research

                                          Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

                                          by Zacks Equity Research

                                          Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

                                            Zacks Equity Research

                                            Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data

                                            by Zacks Equity Research

                                            Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.

                                              Zacks Equity Research

                                              Pfizer Gets FDA Nod for Amgen, J&J's Anemia Drug Biosimilar

                                              by Zacks Equity Research

                                              Pfizer's (PFE) Retacrit, a biosimilar of Amgen's Epogen and J&J's Procrit gets FDA approval. The drug will be available for the treatment of anemia.

                                                Zacks Equity Research

                                                Eli Lilly's Cluster Headache Candidate Succeeds in Phase III

                                                by Zacks Equity Research

                                                Eli Lilly's (LLY) galcanezumab meets the primary endpoint in a late-stage study evaluating it for the prevention of episodic cluster headache.

                                                  Zacks Equity Research

                                                  Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss

                                                  by Zacks Equity Research

                                                  Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.